Generic Somatropin NDAs Would Require Human Immunogenicity Tests – FDA
Executive Summary
Approval of "interchangeable" growth hormone products would require human immunogenicity safety studies under a draft guidance being vetted at FDA
You may also be interested in...
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins
Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone